RHON-KLINIKUM AG, one of Germany's largest healthcare providers, has announced a stable business performance for the first half of 2026, with revenues reaching EUR 863.6 million, slightly exceeding the previous year's figure of EUR 833.5 million. The company's EBITDA increased to EUR 57.0 million from EUR 46.7 million, and consolidated profit rose to EUR 22.5 million, up from EUR 14.7 million in the same period of 2025. The results were significantly impacted by immediate transformation costs established to offset higher personnel and material costs from prior years.
The number of patients treated across the Group's hospitals and medical care centres increased by 9% to 513,700, compared to 471,295 in the first half of 2025. This growth underscores the company's ongoing efforts to expand and improve regional healthcare provision. Investments in state-of-the-art medical technology are planned for 2026 at all sites, alongside further developments in medical and therapeutic care offerings and the establishment of regional cooperation networks.
Notably, in Hesse, Universitatsklinikum Marburg and the pulmonary clinic Lungenfachklinik Immenhausen have formed a strategic partnership to enhance the care of lung patients. In Brandenburg, the newly opened child protection emergency service at the RHON-KLINIKUM Frankfurt (Oder) site has strengthened the regional network, with cooperation agreements signed between the hospital, the City of Frankfurt (Oder), and the District of Oder-Spree to ensure coordinated and effective help for affected children and adolescents.
Dr. Gunther K. WeiB, member of the Board of Management, emphasized the importance of regional networks in the future healthcare system. "Rigid sectoral boundaries make it more difficult to provide patients with the care they need and saddle our healthcare system with unnecessary costs," he said. "It is only when general practitioners, specialists, medical facilities, nurses and therapists work together as a team that we can pool our resources efficiently. In the face of mounting pressures, such collaboration across providers is the only way to ensure comprehensive and high-quality care to patients, especially in rural areas."
However, the company faces significant challenges from upcoming reforms. Dr. Stefan Stranz, also a member of the Board of Management, criticized the Statutory Health Insurance Contribution Rate Stabilization Act, stating that it "imposes further burdens on hospitals. Instead of reducing bureaucracy and refocusing on patient care, the reform saddles already overburdened hospitals with even more documentation requirements, excessive budget cuts, and financial risks."
Looking ahead to the full year 2026, RHON-KLINIKUM AG expects revenues of EUR 1.7 billion within a range of plus or minus 5%, and EBITDA between EUR 110 million and EUR 125 million. The company also anticipates moderate improvements in non-financial performance indicators, such as number of cases and cost weights. However, the forecast is subject to considerable uncertainties due to the ongoing legislative process, particularly the Hospital Reform Adjustment Act (KHAG) and the GKV Contribution Rate Stabilisation Act (GKV-BStabG), which aim to enhance quality and efficiency but may increase financial pressure on hospitals in the short term.
The company notes that the full impact of regulatory interference, implementation of hospital reform, and further legislative adjustments cannot be reliably predicted at this time. Global crises and negative economic impacts, including higher prices, supply bottlenecks, and market volatility, add further uncertainty. The interim report for the first half of 2026 is published on the company's website at www.rhoen-klinikum-ag.com.
